Playback speed
10 seconds
ESMO 2023 Insights: "AIM-HN Study - Evaluating Tipifarnib in mHRAS, Recurrent or Metastatic HNSCC"
By
Dana-Farber Cancer Institute
FEATURING
Robert Haddad
By
Dana-Farber Cancer Institute
FEATURING
Robert Haddad
63 views
November 6, 2023
Login to view comments.
Click here to Login